Sponsor Dossier
Jazz Pharmaceuticals
Sponsor Dossier for Jazz Pharmaceuticals. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
About
Jazz Pharmaceuticals is an Australian Private Company with ABN 83 643 560 534, registered in New South Wales. The entity is active and registered for GST.
Portfolio
Jazz Pharmaceuticals has five brands on the ARTG, with all five cleared the SEO quality gate as indexable brands. All five brands have Product Information on file. One brand is PBS-listed, three brands have PBAC outcomes on record, and four brands have AusPARs on record. Notable brands include DEFITELIO, ENRYLAZE, EPIDYOLEX, Sativex, and VYXEOS.
Therapeutic focus
— Oncology: 2 brands — Neurology: 2 brands — Haematology: 1 brand
PBS footprint
One brand in the Jazz Pharmaceuticals portfolio is PBS-listed, with the latest PBS schedule date touched on 1 May 2026.
Regulatory activity
The latest PBAC outcome for Jazz Pharmaceuticals is dated 1 July 2025, with three brands holding PBAC outcomes on record. The latest AusPAR is dated 10 April 2025, with four brands holding AusPARs on record.